glp 1 drug mounjaro Use of the dual GIP/GLP-1 tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort Could GLP-1 Weight Loss Drugs

Description

however, when rigorously designed using proven analytic approaches to emulate reference trials, real-world evidence of several glucose-lowering drug classes have demonstrated strong concordance with trial estimates 20,22,32

Get a clear, honest opinion from Dr

Kahle MD, PhD To view or add a comment, sign in More Relevant Posts We're excited to announce positive topline data from the ACCESS clinical program of aleniglipron, an orally-available, once-daily, nonpeptide small molecule agonist of the #GLP1 receptor, for the treatment of people living with #obesity and/or overweight with at least one weight-related comorbidity

Please refer to the full 2020 ADA Standards of Care for additional details and recommendations regarding intensification of therapy beyond dual antihyperglycemic therapy

Each of these regions presents unique challenges and opportunities, influenced by local healthcare policies, regulatory frameworks, and cultural attitudes towards obesity and diabetes management